Bayer shares surge after white house backs supreme court review in Roundup case

The stock jumped 14% in early European trading after the U.S. government supported Bayer’s bid to limit long-running litigation over its Roundup weed-killer.

Bayer shares rose as much as 14% in early European trading after the White House expressed support for the company’s request for a U.S. Supreme Court review in the high-profile legal battle over its Roundup herbicide.

Bayer, which has owned Roundup since acquiring Monsanto in 2018, faces tens of thousands of lawsuits in the U.S. Plaintiffs allege that Roundup’s active ingredient, glyphosate, can cause cancer. The company has been working for years to limit the wave of litigation and is asking the Supreme Court to determine whether federal pesticide law should override stricter state-level failure-to-warn requirements.

In its filing, the U.S. government noted that the Environmental Protection Agency has repeatedly found that glyphosate is “not likely to be carcinogenic to humans” and has approved Roundup labels without cancer warnings. This position significantly strengthens Bayer’s legal argument and could reduce the viability of many pending and future claims.

Analysts say the White House’s support is an important step in Bayer’s strategy to resolve glyphosate-related litigation by the end of 2026. The prospect of lower legal exposure immediately boosted investor sentiment, sending Bayer’s shares sharply higher.